Compare · GILD vs SOPH
GILD vs SOPH
Side-by-side comparison of Gilead Sciences Inc. (GILD) and SOPHiA GENETICS SA (SOPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and SOPH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $159.05B, about 420.3x SOPH ($378.4M).
- Over the past year, GILD is up 11.2% and SOPH is up 88.2% - SOPH leads by 77.0 points.
- GILD has been more active in the news (20 items in the past 4 weeks vs 12 for SOPH).
- GILD has more recent analyst coverage (25 ratings vs 13 for SOPH).
- Company
- Gilead Sciences Inc.
- SOPHiA GENETICS SA
- Price
- $125.62-1.99%
- $5.40+2.86%
- Market cap
- $159.05B
- $378.4M
- 1M return
- -4.33%
- +4.25%
- 1Y return
- +11.19%
- +88.15%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 20
- 12
- Recent ratings
- 25
- 13
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
SOPHiA GENETICS SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest GILD
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Latest SOPH
- Chief Financial Officer Cardoza George bought $99,000 worth of Ordinary Shares (20,000 units at $4.95), increasing direct ownership by 7% to 311,458 units (SEC Form 4)
- SEC Form 6-K filed by SOPHiA GENETICS SA
- SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center
- Chief Medical Officer Menu Philippe sold $24,774 worth of Ordinary Shares (5,000 units at $4.95) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 250,780 units (SEC Form 4)
- President Muken Ross sold $3,501 worth of Ordinary Shares (761 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.11% to 680,911 units (SEC Form 4) (tax liability)
- Chief Scientific Officer Xu Zhenyu sold $2,798 worth of Ordinary Shares (608 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.10% to 626,280 units (SEC Form 4) to satisfy tax liability
- Chief Executive Officer Camblong Jurgi sold $20,658 worth of Ordinary Shares (4,486 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.12% to 3,629,495 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Menu Philippe sold $2,800 worth of Ordinary Shares (608 units at $4.61) as part of a pre-agreed trading plan, decreasing direct ownership by 0.24% to 255,780 units (SEC Form 4) (tax withholding)
- Chief Legal Officer Van Well Daan sold $3,149 worth of Ordinary Shares (684 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.20% to 345,052 units (SEC Form 4) to satisfy tax liability
- Chief People Officer Valente Manuela sold $1,747 worth of Ordinary Shares (380 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.18% to 214,691 units (SEC Form 4) (tax withholding)